Thursday, August 2, 2007 - 8:25 AM
S161
Biocatalysis: Synthesis of Chiral Pharmaceutical Intermediates
Ramesh N. Patel, Prcess Research & Development, Bristol-Myers Squibb, One Squibb Drive, Bridgewater, NJ 08903
ABSTRACT
The production of single enantiomers of chiral intermediates has become increasingly important in the pharmaceuticals. Single enantiomers can be produced by chemical or chemo-enzymatic synthesis. The advantages of biocatalysis over chemical synthesis are that enzyme-catalyzed reactions are often highly enantioselective, regioselective and can be carried out at ambient temperature and atmospheric pressure. In addition, enzymes can be overexpressed and immobilized for reusability to make biocatalytic processes efficient. Recently directed evolution of biocatalysts has been used to make tailor-made enzymes useful in the catalysis of non-natural substrates. In this presentation, microbial/enzymatic processes will be described for the preparation of chiral intermediates for antiviral agent, antidiabetic drug, anticancer agents, antianxiety drug, and anti-Alzheimer's drug.
The production of single enantiomers of chiral intermediates has become increasingly important in the pharmaceuticals. Single enantiomers can be produced by chemical or chemo-enzymatic synthesis. The advantages of biocatalysis over chemical synthesis are that enzyme-catalyzed reactions are often highly enantioselective, regioselective and can be carried out at ambient temperature and atmospheric pressure. In addition, enzymes can be overexpressed and immobilized for reusability to make biocatalytic processes efficient. Recently directed evolution of biocatalysts has been used to make tailor-made enzymes useful in the catalysis of non-natural substrates. In this presentation, microbial/enzymatic processes will be described for the preparation of chiral intermediates for antiviral agent, antidiabetic drug, anticancer agents, antianxiety drug, and anti-Alzheimer's drug.